Equities research analysts expect ConforMIS Inc (NASDAQ:CFMS) to announce earnings per share of ($0.30) for the current quarter, Zacks reports. Five analysts have made estimates for ConforMIS’s earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.38). ConforMIS reported earnings per share of ($0.37) in the same quarter last year, which would indicate a positive year-over-year growth rate of 18.9%. The business is expected to announce its next earnings results on Wednesday, February 21st.

On average, analysts expect that ConforMIS will report full year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.34) to ($1.22). For the next financial year, analysts forecast that the business will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.09) to ($0.94). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for ConforMIS.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. ConforMIS had a negative return on equity of 76.88% and a negative net margin of 72.70%. The company had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.55 million. During the same period in the prior year, the firm earned ($0.31) earnings per share. The firm’s revenue was down 1.3% compared to the same quarter last year.

A number of research firms have commented on CFMS. BTIG Research upgraded ConforMIS from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Wednesday, December 20th. Zacks Investment Research cut ConforMIS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Finally, ValuEngine upgraded ConforMIS from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $5.54.

ConforMIS (CFMS) traded down $0.04 during trading hours on Friday, reaching $2.46. The company’s stock had a trading volume of 258,500 shares, compared to its average volume of 332,286. The company has a quick ratio of 5.38, a current ratio of 6.19 and a debt-to-equity ratio of 0.52. ConforMIS has a one year low of $2.21 and a one year high of $8.72. The firm has a market capitalization of $113.23, a PE ratio of -1.84 and a beta of 2.21.

In other news, CEO Mark A. Augusti sold 16,548 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $2.27, for a total transaction of $37,563.96. Following the sale, the chief executive officer now owns 285,007 shares of the company’s stock, valued at $646,965.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Paul S. Weiner sold 17,723 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $3.17, for a total value of $56,181.91. Following the sale, the chief financial officer now directly owns 162,009 shares in the company, valued at approximately $513,568.53. The disclosure for this sale can be found here. Insiders have sold 85,994 shares of company stock worth $244,696 in the last ninety days. Corporate insiders own 9.55% of the company’s stock.

Several institutional investors have recently bought and sold shares of CFMS. Stonebridge Capital Management Inc. purchased a new stake in shares of ConforMIS during the third quarter worth $130,000. The Manufacturers Life Insurance Company increased its position in shares of ConforMIS by 21.4% during the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after acquiring an additional 6,535 shares during the period. Alliancebernstein L.P. increased its position in shares of ConforMIS by 31.1% during the second quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 9,500 shares during the period. Rhumbline Advisers increased its position in shares of ConforMIS by 21.8% during the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock worth $192,000 after acquiring an additional 8,017 shares during the period. Finally, Swiss National Bank increased its position in shares of ConforMIS by 59.2% during the second quarter. Swiss National Bank now owns 53,500 shares of the medical instruments supplier’s stock worth $230,000 after acquiring an additional 19,900 shares during the period. 35.57% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/29/brokerages-expect-conformis-inc-cfms-will-post-earnings-of-0-30-per-share.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Get a free copy of the Zacks research report on ConforMIS (CFMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.